List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7312989/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank. Psychological Medicine, 2023, 53, 3000-3008.	4.5	9
2	Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption. Psychological Medicine, 2022, 52, 726-736.	4.5	33
3	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	2.2	31
4	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. Journal of Affective Disorders, 2022, 296, 485-492.	4.1	3
5	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. European Neuropsychopharmacology, 2022, 55, 86-95.	0.7	19
6	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 114, 110480.	4.8	3
7	Gambling Disorder in an Italian Population: Risk of Suicide Attempts and Associated Demographic-Clinical Factors using Electronic Health Records. Journal of Gambling Studies, 2022, 38, 1143-1156.	1.6	3
8	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. International Clinical Psychopharmacology, 2022, 37, 38-45.	1.7	9
9	Anxiety disorders and age-related changes in physiology. British Journal of Psychiatry, 2022, 221, 528-537.	2.8	10
10	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts. British Journal of Psychiatry, 2022, 221, 722-731.	2.8	4
11	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 715-727.	3.2	14
12	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. European Neuropsychopharmacology, 2022, 56, 100-111.	0.7	5
13	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts – ERRATUM. British Journal of Psychiatry, 2022, , 1-2.	2.8	0
14	Anxiety disorders and age-related changes in physiology – ERRATUM. British Journal of Psychiatry, 2022, , 1-1.	2.8	1
15	Polygenic risk scores for neuropsychiatric, inflammatory, and cardioâ€metabolic traits highlight possible genetic overlap with suicide attempt and treatmentâ€emergent suicidal ideation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2022, 189, 74-85.	1.7	8
16	Genetics in psychiatry: Methods, clinical applications and future perspectives. , 2022, 1, .		3
17	COVID-19 hospitalization rates in individuals with substance or alcohol use disorders. Psychiatry Research, 2022, 311, 114521.	3.3	11
18	Imputed expression of schizophreniaâ€associated genes and cognitive measures in patients with schizophrenia. Molecular Genetics & Genomic Medicine, 2022, 10, e1942.	1.2	6

#	Article	IF	CITATIONS
19	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. Journal of Affective Disorders, 2022, 312, 225-234.	4.1	2
20	Pharmacogenetics in psychiatry: some key clinical considerations. Minerva Psychiatry, 2022, 63, .	0.3	0
21	The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?. International Clinical Psychopharmacology, 2022, 37, 263-275.	1.7	9
22	Clinical, demographic, and genetic risk factors of treatmentâ€attributed suicidality in >10,000 Australian adults taking antidepressants. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2022, 189, 196-206.	1.7	2
23	Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder. Journal of Clinical Medicine, 2022, 11, 3935.	2.4	7
24	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110050.	4.8	21
25	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. Journal of Affective Disorders, 2021, 279, 722-729.	4.1	7
26	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110170.	4.8	36
27	Precision psychiatry in clinical practice. International Journal of Psychiatry in Clinical Practice, 2021, 25, 19-27.	2.4	25
28	Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression. Pharmacogenomics Journal, 2021, 21, 85-93.	2.0	1
29	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. Molecular Psychiatry, 2021, 26, 3363-3373.	7.9	66
30	Genome-wide association study of suicidal behaviour severity in mood disorders. World Journal of Biological Psychiatry, 2021, 22, 1-19.	2.6	3
31	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. Journal of Affective Disorders, 2021, 286, 149-157.	4.1	4
32	Genetic underpinnings of sociability in the general population. Neuropsychopharmacology, 2021, 46, 1627-1634.	5.4	18
33	Oral Microbiome Dysbiosis Is Associated With Symptoms Severity and Local Immune/Inflammatory Response in COVID-19 Patients: A Cross-Sectional Study. Frontiers in Microbiology, 2021, 12, 687513.	3.5	88
34	Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. Neuropsychopharmacology, 2021, 46, 1821-1829.	5.4	27
35	Pharmacogeneticâ€Guided Treatment of Depression: Realâ€World Clinical Applications, Challenges, and Perspectives. Clinical Pharmacology and Therapeutics, 2021, 110, 573-581.	4.7	11
36	Sexâ€related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. Depression and Anxiety, 2021, 38, 896-906.	4.1	18

#	Article	IF	CITATIONS
37	Melancholic features in major depression – a European multicenter study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110285.	4.8	17
38	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. Current Medicinal Chemistry, 2021, 28, 4296-4320.	2.4	1
39	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. Journal of Psychiatric Research, 2021, 141, 167-175.	3.1	14
40	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2021, , .	2.1	2
41	Vitamin D and the risk of treatment-resistant and atypical depression: A Mendelian randomization study. Translational Psychiatry, 2021, 11, 561.	4.8	9
42	An interview with Dr Chiara Fabbri: pharmacogenomics and drug repurposing for treatment-resistant depression. Pharmacogenomics, 2021, 22, 1107-1109.	1.3	0
43	Comparison of Mortality Rates between Italian and Foreign-born Patients with Alcohol Use Disorders. Journal of Psychoactive Drugs, 2021, , 1-11.	1.7	0
44	Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. Pharmacogenomics Journal, 2020, 20, 329-341.	2.0	45
45	Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. Neuroscience Letters, 2020, 726, 133651.	2.1	14
46	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 901-910.	3.2	8
47	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. European Neuropsychopharmacology, 2020, 41, 70-80.	0.7	14
48	Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. International Clinical Psychopharmacology, 2020, 35, 233-242.	1.7	22
49	The Role of Genetics in Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2020, 48, 41-60.	1.7	10
50	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. International Journal of Neuropsychopharmacology, 2020, 23, 571-577.	2.1	5
51	Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture. BMC Microbiology, 2020, 20, 120.	3.3	152
52	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Translational Psychiatry, 2020, 10, 50.	4.8	33
53	Genetic variants associated with psychotic symptoms across psychiatric disorders. Neuroscience Letters, 2020, 720, 134754.	2.1	9
54	Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. Clinical Psychopharmacology and Neuroscience, 2020, 18, 1-9.	2.0	23

#	Article	IF	CITATIONS
55	How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. Clinical Psychopharmacology and Neuroscience, 2020, 18, 484-492.	2.0	14
56	The search for personalized antidepressant treatments: what have we learned and where are we going. Pharmacogenomics, 2020, 21, 1095-1100.	1.3	2
57	Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 23-29.	4.8	13
58	Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. World Journal of Biological Psychiatry, 2019, 20, 427-448.	2.6	89
59	Is Pharmacogenetics Useful in Antidepressant Treatment?. Clinical Pharmacology and Therapeutics, 2019, 106, 916-918.	4.7	2
60	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology, 2019, 29, 971-985.	0.7	93
61	F105AN EXOME SEQUENCING STUDY IN TREATMENT-RESISTANT DEPRESSION. European Neuropsychopharmacology, 2019, 29, S1166-S1167.	0.7	0
62	META-ANALYSIS OF CYP2C19 ASSOCIATION WITH EFFICACY AND SIDE EFFECTS OF CITALOPRAM AND ESCITALOPRAM USING DATA FROM GENOME-WIDE ASSOCIATION STUDIES. European Neuropsychopharmacology, 2019, 29, S808.	0.7	0
63	Manifesto for an international digital mental health network. Digital Psychiatry, 2019, 2, 14-24.	2.1	14
64	PHARMACOGENETIC TESTING IN PSYCHIATRY: CRITICAL REVIEW OF EXISTING TESTING KITS AND CLINICAL TRIALS. European Neuropsychopharmacology, 2019, 29, S1064-S1065.	0.7	0
65	WHOLE EXOME SEQUENCING REVEALS RISK FACTORS IN TREATMENT RESISTANT DEPRESSION. European Neuropsychopharmacology, 2019, 29, S934-S935.	0.7	0
66	Uncovering neurodevelopmental features in bipolar affective disorder. British Journal of Psychiatry, 2019, 215, 383-385.	2.8	13
67	Single nucleotide polymorphisms (SNPs) implicated in determining predominant polarity in bipolar disorder. European Neuropsychopharmacology, 2019, 29, S378-S379.	0.7	0
68	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. Journal of Affective Disorders, 2019, 249, 410-417.	4.1	12
69	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. Neuropsychobiology, 2019, 77, 67-72.	1.9	13
70	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. British Journal of Psychiatry, 2019, 214, 36-41.	2.8	44
71	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatrica Scandinavica, 2019, 139, 78-88.	4.5	92
72	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. International Journal of Neuropsychopharmacology, 2019, 22, 93-104.	2.1	32

#	Article	IF	CITATIONS
73	Pharmacogenetics and Depression: A Critical Perspective. Psychiatry Investigation, 2019, 16, 645-653.	1.6	17
74	Highlights on Pharmacogenetics and Pharmacogenomics in Depression. , 2018, , 3-16.		0
75	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 203-210.	4.8	31
76	New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics Journal, 2018, 18, 413-421.	2.0	40
77	The serotonin transporter and the activity regulated cytoskeletonâ€associated protein genes in antidepressant response and resistance: <scp>5â€HTTLPR</scp> and other variants. Human Psychopharmacology, 2018, 33, e2682.	1.5	7
78	Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 36-44.	4.8	39
79	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.7	64
80	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). Translational Psychiatry, 2018, 8, 150.	4.8	19
81	Genetic disposition to inflammation and response to antidepressants in major depressive disorder. Journal of Psychiatric Research, 2018, 105, 17-22.	3.1	18
82	Clinical efficacy of a chlorhexidineâ€based mouthrinse containing hyaluronic acid and an antidiscoloration system in patients undergoing flap surgery: A tripleâ€blind, parallelâ€arm, randomized controlled trial. International Journal of Dental Hygiene, 2018, 16, 541-552.	1.9	10
83	No Association Between Antidepressant Efficacy and rs28365143 in Corticotropin-Releasing Hormone Binding Protein in a Large Meta-Analysis. American Journal of Psychiatry, 2018, 175, 575-576.	7.2	1
84	Pharmacogenetics in Psychiatry. Advances in Pharmacology, 2018, 83, 297-331.	2.0	31
85	22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders. Lancet Psychiatry,the, 2018, 5, 531-532.	7.4	1
86	International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacological Reviews, 2018, 70, 475-504.	16.0	42
87	Refining Prediction in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2018, 79, 16m11385.	2.2	76
88	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	4.8	71
89	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 723-735.	3.2	21
90	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 482-490.	2.5	10

#	Article	IF	CITATIONS
91	Is a polygenic predictor of antidepressant response a possibility?. Pharmacogenomics, 2017, 18, 749-752.	1.3	4
92	New Insights Into The Pharmacogenomics Of Antidepressant Response From The Gendep And Star*D Studies: Results Of Rare Variant Analysis And High-Density Imputation. European Neuropsychopharmacology, 2017, 27, S443-S444.	0.7	0
93	Cariprazine specificity profile in the treatment of acute schizophrenia. International Clinical Psychopharmacology, 2017, 32, 309-318.	1.7	27
94	Role of 108 schizophreniaâ€associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 757-764.	1.7	38
95	Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World Journal of Biological Psychiatry, 2017, 18, 5-28.	2.6	75
96	Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram. European Neuropsychopharmacology, 2017, 27, S582-S583.	0.7	0
97	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. European Neuropsychopharmacology, 2017, 27, S583.	0.7	0
98	Potential genes behind the difference between bipolar I and bipolar II disorder. European Neuropsychopharmacology, 2017, 27, S836-S837.	0.7	0
99	Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder. European Neuropsychopharmacology, 2017, 27, S1057-S1058.	0.7	0
100	Genetic and Environmental Contribution to Major Depressive Disorder and Self-declared Depression. EBioMedicine, 2016, 14, 7-8.	6.1	10
101	ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors. European Neuropsychopharmacology, 2016, 26, S240-S241.	0.7	0
102	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv125.	2.1	26
103	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry, 2016, 16, 172.	2.6	16
104	Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1157-1168.	3.3	30
105	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry, 2016, 16, 106.	2.6	24
106	Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 703-717.	3.2	24
107	Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs. , 2016, , 39-54.		1
108	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. Neuropsychobiology, 2016, 73, 35-42.	1.9	21

#	Article	IF	CITATIONS
109	Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders. Metabolic Brain Disease, 2016, 31, 183-189.	2.9	6
110	Genetics of long-term treatment outcome in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 65, 17-24.	4.8	39
111	Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors. Psychiatry Investigation, 2016, 13, 247.	1.6	15
112	The Role of Pharmacogenetics in Pharmacovigilance of Psychotropic Drugs. , 2016, , 121-146.		0
113	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. Neuropsychobiology, 2015, 72, 118-125.	1.9	8
114	Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder. Pharmacogenetics and Genomics, 2015, 25, 354-362.	1.5	15
115	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. Journal of Clinical Psychopharmacology, 2015, 35, 220-227.	1.4	22
116	Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications. Current Psychiatry Reports, 2015, 17, 50.	4.5	69
117	Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics. Neuropsychobiology, 2015, 71, 218-224.	1.9	29
118	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. Journal of Neural Transmission, 2015, 122, 43-58.	2.8	14
119	A model to investigate SNPs' interaction in GWAS studies. Journal of Neural Transmission, 2015, 122, 145-153.	2.8	3
120	CHL1,ITGB3andSLC6A4gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. Pharmacogenomics, 2015, 16, 689-701.	1.3	22
121	Antagonist and partial agonist at the dopamine D2 receptors in drug-naÃ ⁻ ve and non-drug-naÃ ⁻ ve schizophrenia: a randomized, controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 579-588.	3.2	5
122	Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics Journal, 2015, 15, 538-548.	2.0	34
123	Predictors of switch from depression to mania in bipolar disorder. Journal of Psychiatric Research, 2015, 66-67, 45-53.	3.1	26
124	P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder. European Neuropsychopharmacology, 2015, 25, S159-S160.	0.7	0
125	Pharmacogenetics of Antidepressant Drugs. , 2014, , 543-562.		0
126	Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. Human Psychopharmacology, 2014, 29, 388-391.	1.5	11

#	Article	IF	CITATIONS
127	Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder. Molecular Diagnosis and Therapy, 2014, 18, 567-577.	3.8	19
128	DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. Journal of Affective Disorders, 2014, 168, 91-97.	4.1	15
129	Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1093-1118.	3.3	14
130	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics Journal, 2014, 14, 463-472.	2.0	41
131	P.1.014 PPP3CC: a new candidate gene in antidepressant response. European Neuropsychopharmacology, 2014, 24, S14-S15.	0.7	0
132	From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment. Canadian Journal of Psychiatry, 2014, 59, 62-75.	1.9	46
133	Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology, 2013, 227, 509-519.	3.1	51
134	Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 487-520.	1.7	77
135	S.25.03 Pharmacogenetics of efficacy and treatment side effects in bipolar disorder. European Neuropsychopharmacology, 2013, 23, S148.	0.7	0
136	Early antidepressant efficacy modulation by glutamatergic gene variants in the STARâŽD. European Neuropsychopharmacology, 2013, 23, 612-621.	0.7	26
137	Clinical features and drug induced side effects in early versus late antidepressant responders. Journal of Psychiatric Research, 2013, 47, 1309-1318.	3.1	26
138	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. European Neuropsychopharmacology, 2013, 23, S168-S169.	0.7	0
139	P.2.f.014 PPP3CC gene in antidepressant response: results from three independent samples. European Neuropsychopharmacology, 2013, 23, S403.	0.7	0
140	Shared genetics among major psychiatric disorders. Lancet, The, 2013, 381, 1339-1341.	13.7	70
141	Pharmacogenetics in major depression: A comprehensive meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 183-194.	4.8	174
142	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. Journal of Psychopharmacology, 2013, 27, 616-628.	4.0	19
143	TPH1, MAOA, Serotonin Receptor 2A and 2C Genes in Citalopram Response: Possible Effect in Melancholic and Psychotic Depression. Neuropsychobiology, 2013, 67, 41-47.	1.9	30
144	Genetics of Serotonin Receptors and Depression: State of the Art. Current Drug Targets, 2013, 14, 531-548.	2.1	26

CHIARA FABBRI

#	Article	IF	CITATIONS
145	No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression. Psychiatry Investigation, 2013, 10, 180.	1.6	20
146	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. European Neuropsychopharmacology, 2012, 22, 239-258.	0.7	283
147	Mechanisms of antidepressant action: An integrated dopaminergic perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1532-1543.	4.8	38
148	P.2.c.026 Rapid versus slow titration of paroxetine antidepressant treatment in elderly population: an observational study. European Neuropsychopharmacology, 2011, 21, S397-S398.	0.7	0
149	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1101-1115.	3.3	64
150	Pharmacogenetics of Antidepressants. Frontiers in Pharmacology, 2011, 2, 6.	3.5	72
151	Pharmacogenetics of antidepressant response. Journal of Psychiatry and Neuroscience, 2011, 36, 87-113.	2.4	144
152	Abnormal brain hemodynamic responses during passive orthostatic challenge in panic disorder. American Journal of Psychiatry, 1997, 154, 378-383.	7.2	26